NCT02044627View on ClinicalTrials.gov

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Hyperlipidemia
Interventions
DRUG

[14C-ETC-1002]

Trial Locations (1)

NG11 6Js

Quotient Clinical, Nottingham

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY